Related Experiment Video
Updated: Feb 11, 2026
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Differential diagnosis and management of polycythemia
Athina Pappas1, Virginia Delaney-Black
1Division of Neonatal-Perinatal Medicine, Wayne State University School of Medicine, Children's Hospital of Michigan, 3901 Beaubien, Detroit, MI 48201, USA.
Insights
Neonatal polycythemia affects 1-5% of US newborns. While high blood viscosity can risk organ blood flow, few infants develop complications, yet treatment decisions remain debated.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
Background:
- Neonatal polycythemia, characterized by elevated venous hematocrit (>65%), affects 1-5% of US newborns.
- Increased blood viscosity in polycythemia can potentially impair organ perfusion.
- Despite risks, complications directly attributable to hyperviscosity are infrequent in affected infants.
Purpose of the Study:
- To review the differential diagnosis of neonatal polycythemia.
- To describe the clinical presentation of polycythemic newborns.
- To discuss current treatment strategies for neonatal polycythemia and hyperviscosity.
Main Methods:
- Literature review of neonatal polycythemia and hyperviscosity.
- Analysis of diagnostic criteria and clinical manifestations.
- Evaluation of existing treatment protocols and their controversies.
Main Results:
- Neonatal polycythemia is diagnosed when venous hematocrit exceeds 65%.
- Elevated blood viscosity is a direct consequence of polycythemia.
- The precise identification of at-risk infants requiring treatment is an area of ongoing debate.
Conclusions:
- Neonatal polycythemia presents a diagnostic and therapeutic challenge.
- Further research is needed to clarify which infants are at risk and necessitate intervention.
- This review provides a framework for understanding the diagnosis, presentation, and management of neonatal polycythemia.
Abstract:
One percent to 5% of all newborns in the United States are polycythemic.As the venous hematocrit rises above 65%, the thickness or viscosity of whole blood also increases, potentially compromising blood flow to a variety of organs. Fortunately, relatively few infants who have neonatal polycythemia or hyperviscosity develop complications attributable to their thick blood; however, controversy and the need for continued research envelop the issue of which infants are at risk and need to be treated. This article reviews the differential diagnosis, clinical presentation, and treatment of neonatal polycythemia.
